Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
True, still, point is to increase institutional support...which this news..is good...looking forward to seeing additional new holders...if there are more.
Better than no institutional support.
Agreed
1 in august and 7 in september
Interesting tweet
Corker + Pointer + GSE Credit Default Swaps (Say It Isn’t So)
As of his CY 2013 Financial Disclosure Form, Senator Bob Corker owned between $5 million and $25 million of a HEDGE FUND named Pointer (guess those hedgies ain’t too bad, huh Bob?)
2. In 2008, Pointer owned GSE Credit Default Swaps and financially benefited from the Government’s takeover of the GSEs.
3. Senator Corker recently called for the investing public to short the GSEs on a nationally televised financial news show.
4. This doesn’t mean that Pointer is currently short the GSEs, but they (and other hedge funds that Senator Corker owns) could be (or could have been) during Senator Corker’s lengthy and ongoing efforts to destroy the GSEs, which raises some interesting questions…
Ever since they added those vid type ads it started getting finiky....could also be IOs updates....had issues with alot or apps freezing after that last update
It was spotty and freezing last week...support told me to delete it and reinstall it. I even had stock boards disappearing so I had to re follow.
Lol
Understood thank you
So basically by dec time frame too or possible Jan for the data? They started it in nov of last year. Thought these studies are usually for 6 months.
Shouldn't Plexxikons be done by now? It's a mouse study correct....interested in seeing how they did in combination with that drug.
Excellent input Guti and great to hear you on this board....
Fanningate....up next
I am showing 150,000 shares direct purchase or almost $918,000? Am i reading it wrong?
Ridgeback is run by Wayne Holman. He is an ex Sac capital trader and helps advise Steve Cohen on positions. His hedge fund is healthcare focused. Volume has increased and is consistent which is nice to see.
Anyone know or have an estimate of when the Plexxikon mouse trial will wrap up? Should we be getting this data soon? Trial announcement was last Nov.
Lol
Yes absolutely...still looking forward to that PLX3397 combination test through Plexxikon. Actually, through anything that validates the immunopulse treatment method further.
Ahh my bad...meant it for Plexxikon test results not Perkins...should be wrapping up..thanks for the catch and no need to be touchy good Dr.
Yes a mention of their test with immunopulse and possible results would be great. Their drug was a hit last year in their trial.
Could be plain window dressing as its the last day of the trading month. A lot of funds and hedge funds use this tactic to boost monthly return numbers. Small price stock can be moved easily with large trades. Jmho
Thanks for input..
Still don't get why insider purchases not allowed currently. Thoughts from anyone?
Agreed provided we get high institutional holders with the lower float...should be interesting.
At $5, mutual funds can buy in most instances i think. Small cap funds and etfs
Dont really know but possible
Sorry 1 for 20 not 20 for 1
Yes agreed. As long as we end up on nasdaq or nyse if real. Aig did a 1-20 before too to $20 now $59. Not sure if real until we hear from company. Not always a bad thing if we can uplist not stay on otc.
Not halfved, its 160m shares so 20 for 1, bringing it to $5.50 per share, over min share price requirements for most exchanges. If correct
Yes they partnered with Oncs last Nov to test combination with immunopulse.
SAN DIEGO--(BUSINESS WIRE)--OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced a preclinical collaboration with Plexxikon Inc., a member of the Daiichi Sankyo Group and leader in the discovery and development of novel small molecule pharmaceuticals, to test the combination of Plexxikon’s selective CSF-1R inhibitor with OncoSec’s Immunopulse pIL-12.
OncoSec’s Chief Scientific Officer, Robert H. Pierce, M.D., said: “Plexxikon is on the cutting edge of developing potent, highly-selective small molecule inhibitors of CSF-1R, a key cell surface receptor, which controls macrophage development and function. Intratumoral macrophages and other related cell types, like myeloid-derived suppressor cells, can be strongly immunosuppressive and block anti-tumor immunity. Given our understanding of IL-12 as a potent driver of immunogenicity and tumor-infiltrating lymphocytes (TILs) and the potential role of tumor-resident myeloid cells in suppressing the anti-tumor effects of TILs, we hypothesize that blocking CSF-1R with Plexxikon’s selective CSF-1R inhibitor will lead to synergistic effects in the syngeneic B16.F10 melanoma mouse model.”
Mai H. Le, M.D., OncoSec’s Chief Medical Officer, commented: “Combination immune therapies, whether small molecules or biologics, will be the norm in the future. There is already considerable discussion in the oncology community regarding the need to find a rational approach to guide immune-focused combinations in the clinic. These initial studies are designed to test the rationale of our combination approach.”
Interleukin-12 (IL-12) is an inflammatory cytokine that is believed to be a master regulator of the immune system, and is important in the up-regulation of both the innate and adaptive immune responses. IL-12 is a key driver of the cascade of biological events which ultimately lead to T-cell-specific killing of cancer cells. Moreover, cytokines and chemokines induced by this pathway also increase the recruitment of inflammatory T-cells into tumors.
ImmunoPulse is a proprietary investigational electroporation device that delivers plasmid IL-12 DNA directly into tumors. By locally delivering and expressing IL-12, ImmunoPulse drives a strong anti-tumor immune response, which can lead not only to local tumor regression, but also systemic anti-tumor responses, while avoiding toxicities caused by systemic administration of IL-12. Recent interim data from OncoSec’s ongoing Phase II clinical study in melanoma have demonstrated that local delivery of IL-12 by electroporation increases the production of cytokines like IFN-?, resulting in increased expression of genes related to the processes required for cytotoxic CD8+ T cells to recognize and kill cancer cells.
About PLX’s highly-specific small molecule inhibitors of CSF-1R
Plexxikon is currently exploring the role of CSF-1R-targeted immune therapy as a sensitizer to chemo- and radiation-therapy, in addition to its potential to augment response to complementary immunotherapies.
The plexxikon drug they are testing with has already been tested in humans but with a rare joint disorder. They were at asco last year and presented. Here's a link
http://finance.yahoo.com/news/plexxikon-announces-promising-preliminary-plx3397-210000558.html;_ylt=A0SO8xQ5fz1VfUQAKznBGOd_;_ylu=X3oDMTE0cGE0OGoxBHNlYwNzcgRwb3MDOARjb2xvA2dxMQR2dGlkA1RBVVMwOThfMQ--
The plexxikon drug is impressive on its own...could be interesting if oncs can improve it further. Its a mouse study though right?
Ok thanks
Punit mentioned start of trial "2 2" what does that mean? Or did i hear wrong?
A lot of institutions do not need to report their holdings because this is otc. In reality we won't know who owns what until the uplist unless they want to report it. Ex. Fairholme and ackman do not report their Fnma and fm can positions anymore.
Got to be fake...followed by 105 people but following 1400 others?
Excellent
Capitulation?
Done thanks
Excerpt from new Cato paper - Calabria
The sole authority granted to the Treasury under the GSE provisions of HERA is in the exercise of its rights as a creditor, should it provide assistance to the GSEs. While a creditor can, of course, negotiate certain provisions as a condition of providing credit, under no circumstances can those conditions supersede other provisions of law. The Treasury has no authority to assume the powers of a conservator via its rights as a creditor. The Treasury can no more, as a creditor, bind FHFA’s authorities, than could a holder of bank debt bind the powers of FDIC. Moreover, FHFA, as an independent regulator, has no authority to delegate its powers as a conservator/receiver to the Treasury or any other government agency.
The role of the Treasury was viewed under HERA as that of a creditor. The Treasury was directed to consider issues of priority and protection of the taxpayer. In addition, such assistance was intended to be temporary, as is the nature of credit, rather than perpetual, as is the nature of equity. Put simply Treasury assistance to the GSEs was envisioned to take the form of a senior debt, something like debtor-in-possession financing. Such assistance was not intended to keep the GSEs out of receivership or to transfer losses from creditors to the taxpayer.
Link to full paper
http://object.cato.org/sites/cato.org/files/pubs/pdf/working-paper-25.pdf